AMSTERDAM and CHICAGO, June 2,
2017 /PRNewswire/ -- Royal Philips (NYSE: PHG,
AEX: PHIA), a global leader in health technology, today announced
the debut of IntelliSpace Oncology, a new cloud-based oncology
decision-support solution that offers seamless data integration
across specialties and locations, data-driven decision making, and
tools for proactive patient involvement1. Available
through a single-view dashboard, these capabilities provide
actionable insights for patient-centric care, while also empowering
patients and their families to make the best possible choices
during the care journey.
Philips chose the American Society of Clinical Oncology Annual
Meeting (ASCO) in Chicago, Ill.
(US), which brings together more than 30,000 oncology professionals
from around the world to discuss state-of-the-art treatment
modalities, for the debut of IntelliSpace Oncology. Also showcasing
at the meeting is the company's full suite of integrated oncology
informatics solutions, including Philips IntelliSpace Genomics, an
integrated precision medicine platform with advanced analytics
capabilities, genomics-informed clinical decision support and
clinical trial matching tools to support the implementation and
scaling of informatics-heavy care. Philips portfolio of oncology
informatics solutions also includes IntelliSite Pathology, the
first digital pathology solution to be cleared for primary
diagnostic use in the U.S.
Bringing together key patient and medical data in one
location
Oncology is a complex medical domain, in which
multiple disciplines must collaborate in order to reach accurate
diagnoses and effective treatment plans. Unfortunately, information
is frequently lost in communications between specialties and care
networks, which can lead to critical information being missed. The
IntelliSpace Oncology decision-support solution seamlessly
incorporates all key patient and medical data in one location, to
provide a clear, intuitive view of patient status that facilitates
data-driven clinical decision support. It also offers tools such as patient group
analysis and predictive analytics on current and historical data
and helps to provide
multi-disciplinary oncology care teams with relevant patient
information to enhance team-wide collaboration, communication and
adherence to clinical guidelines.
Proactively keeping patients involved
IntelliSpace
Oncology also offers powerful data mining and analytics
capabilities that integrate a hospital's cancer patient records.
This offers clinicians an extensive patient database, enabling them
to compare their patients' data with that of other patients who
have similar characteristics in order to gain data-driven insights
into treatment choices and the effects those choices have on
patients' quality of life. Patients need to make many difficult
choices about their treatment path and care, so having the ability
to view all the relevant data is key to helping them make solid
decisions along with their doctor. Via this capability,
IntelliSpace Oncology enables deeper patient involvement through
personalized educational materials, access to status dashboards,
patient-reported outcomes and satisfaction surveys, along with
family and care giver support.
Optimization of guideline adherence by 12 percent
Philips IntelliSpace Oncology has been developed with the support
of oncology experts at the Leiden University Medical Center (LUMC)
in the Netherlands. Philips and
LUMC are collaborating in an ongoing pilot study to test the use of
IntelliSpace Oncology in colorectal cancer tumor boards, evaluating
the impact on workflow efficiency and quality of personalized
treatment decisions. During the pilot program, approximately half
the doctors using the solution stated that it shortened the time
spent reviewing each patient case. The program also showed further
optimization of guideline adherence by 12 percent.
"It remains a real challenge to bring all the necessary
information together in order to get a complete picture of the
patient and make a good decision. Typically, the information is
there but it's not organized in a way that supports us during the
decision making process," says oncology surgeon Bert Bonsing, MD,
PhD, of the Leiden University Medical Center. "New technologies can
help us optimize how we work together as a team of specialists with
the aim of giving the patient a therapy that's as personalized as
possible."
"Philips is committed to collaborating with key thought leaders
in oncology to develop innovative digital solutions that offer
connected care and more personalized treatment for cancer
patients," said Yair Briman,
Business Leader, Healthcare Informatics, Philips. "The introduction
of IntelliSpace Oncology, based on our joint efforts with LUMC,
helps to address the real challenges oncology practitioners are
facing today, ultimately driving confident diagnosis through a
holistic, patient-centric approach to cancer care."
Philips teams up with Navican and MSK on precision
medicine
Prior to ASCO Philips announced it is teaming up
with Navican, an Intermountain Healthcare Company, to accelerate
the delivery of precision medicine to health Systems worldwide. The
companies will work together on a new "turnkey" approach to
precision medicine that seeks to deliver Intermountain's best
practices into a streamlined service to be integrated at the point
of care. Next to this, Philips signed an agreement with Memorial
Sloan Kettering Cancer center. Both organizations will work
together to develop new methodologies and informatics
approaches2 for advanced precision diagnostics to help
uncover the drivers for cancer at single-cell level. The results of
the collaboration will be made available as research applications
via the Philips platform to further strengthen next-generation
genomic sequencing data methods, analysis and cancer research.
For more information on the full portfolio of Philips oncology
solutions and Philips' presence at the American Society of Clinical
Oncology Annual Meeting, visit Booth #5107 on the exhibit floor,
and follow @PhilipsLiveFrom for #ASCO17 updates throughout the
event.
For further information, please contact:
Kathy O'Reilly
Philips Group Press Office
Tel: +1 978-221-8919
E-mail: Kathy.Oreilly@Philips.com
Twitter: @kathyoreilly
Joost Maltha
Philips Group Press Office
Tel.: +31 6 10 55 8116
E-mail: Joost.Maltha@philips.com
Twitter: @JoostMaltha
About Royal
Philips
Royal Philips (NYSE: PHG, AEX: PHIA) is a
leading health technology company focused on improving people's
health and enabling better outcomes across the health continuum
from healthy living and prevention, to diagnosis, treatment and
home care. Philips leverages advanced technology and deep clinical
and consumer insights to deliver integrated solutions.
Headquartered in the Netherlands,
the company is a leader in diagnostic imaging, image-guided
therapy, patient monitoring and health informatics, as well as in
consumer health and home care. Philips' health technology portfolio
generated 2016 sales of EUR 17.4
billion and employs approximately 70,000 employees with
sales and services in more than 100 countries. News about Philips
can be found at www.philips.com/newscenter.
1 Work in Progress. IntelliSpace Oncology is
expected to be commercially available Q4 2017.
2 For Research use only and cannot be used for
patient diagnosis or treatment selection
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/philips-showcases-oncology-informatics-solutions-to-deliver-actionable-insights-for-enhanced-clinical-decision-support-at-asco-2017-300467736.html
SOURCE Royal Philips